This week, the overall grades of 32 Biotechnology stocks are lower, according to the Portfolio Grader database. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).

This week, Prothena Corp. Plc’s (PRTA) rating worsens to a D from the company’s C rating a week ago. The company also gets F’s in sales growth, earnings momentum, and return on equity. For more information, get Portfolio Grader’s complete analysis of PRTA stock.

Slipping from a C to a D rating, Alkermes Plc (ALKS) takes a hit this week. Alkermes Plc is a fully integrated biotechnology company committed to developing medicines that will improve patients’ lives. The company also gets F’s in earnings revisions, earnings surprise, and return on equity. For more information, get Portfolio Grader’s complete analysis of ALKS stock.

Kite Pharma, Inc. (KITE) slips from a D to a F this week. The company also gets F’s in earnings momentum and return on equity. For more information, get Portfolio Grader’s complete analysis of KITE stock.

DBV Technologies SA Sponsored ADR (DBVT) gets weaker ratings this week as last week’s C drops to a D. The company also gets F’s in earnings surprise and return on equity. For more information, get Portfolio Grader’s complete analysis of DBVT stock.

This week, Loxo Oncology Inc (LOXO) drops from a C to a D rating. The company also gets F’s in earnings surprise and return on equity. For more information, get Portfolio Grader’s complete analysis of LOXO stock.

Atara Biotherapeutics Inc (ATRA) is having a tough week. The company’s rating falls from a D to a F. The company also gets F’s in earnings revisions, earnings surprise, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of ATRA stock.

Portola Pharmaceuticals, Inc. (PTLA) experiences a ratings drop this week, going from last week’s D to a F. The company also gets F’s in earnings surprise, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of PTLA stock.

Myriad Genetics, Inc. (MYGN) earns a F this week, moving down from last week’s grade of D. Myriad Genetics, Inc. develops and markets molecular diagnostic products to provide physicians with information to help guide the care of their patients, to prevent disease, delay the onset of disease, or catch disease at an early stage. The company also gets F’s in earnings momentum. For more information, get Portfolio Grader’s complete analysis of MYGN stock.

Axovant Sciences Ltd (AXON) declines this week from a C to a D. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of AXON stock.

CytomX Therapeutics, Inc.’s (CTMX) rating weakens this week, dropping to a D versus last week’s B. The company also gets F’s in earnings surprise, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of CTMX stock.

This is a rough week for Advaxis, Inc. (ADXS). The company’s rating falls to D from the previous week’s C. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of ADXS stock.

OPKO Health, Inc.’s (OPK) rating weakens this week, dropping to a D versus last week’s C. OPKO Health, Inc. is involved in the discovery, development, and commercialization of pharmaceutical products, vaccines, and diagnostic products. The company also gets F’s in earnings growth and earnings momentum. For more information, get Portfolio Grader’s complete analysis of OPK stock.

Slipping from a C to a D rating, Amicus Therapeutics, Inc. (FOLD) takes a hit this week. Amicus Therapeutics, Inc. is a biopharmaceutical company which is focused on the discovery, development and commercialization of orally-administered, small molecule drugs known as pharmacological chaperones. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of FOLD stock.

This week, Trillium Therapeutics Inc.’s (TRIL) rating worsens to a D from the company’s C rating a week ago. The company also gets F’s in earnings momentum, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of TRIL stock.

Xenon Pharmaceuticals Inc. (XENE) gets weaker ratings this week as last week’s C drops to a D. The company also gets F’s in sales growth, operating margin growth, earnings growth, earnings surprise, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of XENE stock.

Intec Pharma Ltd (NTEC) slips from a C to a D this week. The company also gets F’s in earnings surprise, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of NTEC stock.

This week, Achillion Pharmaceuticals, Inc. (ACHN) drops from a D to a F rating. Achillion Pharmaceuticals, Inc. focuses on the discovery, development and commercialization of innovative treatments for infectious diseases. The company also gets F’s in sales growth and earnings momentum. For more information, get Portfolio Grader’s complete analysis of ACHN stock.

Genocea Biosciences, Inc. (GNCA) experiences a ratings drop this week, going from last week’s C to a D. The company also gets F’s in sales growth, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of GNCA stock.

DelMar Pharmaceuticals, Inc. (DMPI) is having a tough week. The company’s rating falls from a C to a D. The company also gets F’s in free cash flow. For more information, get Portfolio Grader’s complete analysis of DMPI stock.

Arrowhead Pharmaceuticals, Inc. (ARWR) declines this week from a C to a D. Arrowhead Pharmaceuticals, Inc. a biopharmaceutical company, develops targeted RNAi therapeutics in the United States. The company also gets F’s in sales growth, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of ARWR stock.

This is a rough week for Dicerna Pharmaceuticals, Inc. (DRNA). The company’s rating falls to F from the previous week’s D. The company also gets F’s in sales growth, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of DRNA stock.

Cyclacel Pharmaceuticals, Inc. (CYCC) earns a D this week, moving down from last week’s grade of C. Cyclacel Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the discovery, development and commercialization of mechanism-targeted drugs to treat human cancers and other serious disorders. The company also gets F’s in sales growth, earnings momentum, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of CYCC stock.

Trovagene, Inc. (TROV) slips from a C to a D this week. Trovagene, Inc. is developing a non-invasive testing technology using transrenal nucleic acid (TrNA) markers for infectious diseases, prenatal testing, early detection of cancer, and monitoring of organ and cell transplantation. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of TROV stock.

This week, Ohr Pharmaceutical, Inc.’s (OHRP) rating worsens to a D from the company’s C rating a week ago. Ohr Pharmaceutical, Inc. develops pharmaceuticals for wound care and to treat cachexia. The company also gets F’s in earnings revisions, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of OHRP stock.

Capricor Therapeutics, Inc. (CAPR) gets weaker ratings this week as last week’s C drops to a D. The company also gets F’s in sales growth, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of CAPR stock.

Stellar Biotechnologies, Inc. (SBOT) experiences a ratings drop this week, going from last week’s D to a F. The company also gets F’s in earnings growth, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of SBOT stock.

ContraFect Corp. (CFRX) is having a tough week. The company’s rating falls from a D to a F. The company also gets F’s in earnings surprise, earnings momentum, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of CFRX stock.

Slipping from a C to a D rating, CorMedix Inc. (CRMD) takes a hit this week. CorMedix Inc. is a development-stage pharmaceutical company that seeks to fulfill selected, significant unmet medical needs in the therapeutic areas at the crossroads of cardiac and kidney (renal) disease. The company also gets F’s in sales growth, earnings surprise, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of CRMD stock.

This week, Pieris Pharmaceuticals, Inc. (PIRS) drops from a C to a D rating. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of PIRS stock.

ArQule, Inc. (ARQL) earns a F this week, moving down from last week’s grade of D. ArQule, Inc. is a biotechnology company that is engaged in the research and development of cancer therapeutics. The company also gets F’s in sales growth, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of ARQL stock.

Verastem, Inc. (VSTM) declines this week from a D to a F. Verastem, Inc. is a biopharmaceutical company which is focused on discovering and developing novel drugs that selectively target cancer stem cells in breast and other cancers along with proprietary companion diagnostics. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of VSTM stock.

Actinium Pharmaceuticals, Inc.’s (ATNM) rating weakens this week, dropping to a F versus last week’s D. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of ATNM stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.